5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,
Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi ...
Voir le projet
13
Participants partenaires
TERMINÉ
Biomarker Research Alliance for Diagnosing Heart Disease in the Ageing European Population (BESTAGEING)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,
The ageing of the European population represents a rapidly rising social and economic challenge. Especially cardiovascular morbidity increases with age, but unfortunately, elderly patients are often difficult to diagnose due to confounding factors, leading to uncertainties in clinical decision making with huge impact on patients’ outcomes. Hence, there is an unmet need for novel biomarkers for mor ...
Voir le projet
22
Participants partenaires
TERMINÉ
European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet
29
Participants partenaires
TERMINÉ
A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches (EUROSTAM)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2015,
The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they don’t have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sens ...
Voir le projet
11
Participants partenaires
TERMINÉ
Validation of diagnostic and/or prognostic miRNAs in triple-negative breast cancer (MIRCAB)
Date du début: 1 janv. 2015, Date de fin: 30 juin 2015,
Multiplicom will draft a business plan that is composed of the following parts:(i) selection of miRNAs for which there is substantial scientific evidence that such may be important for the diagnosis, treatment and/or prognosis of triple-negative breast cancer (“TNBC”) patients;(ii) perform a thorough analysis of the intellectual property on the selected miRNAs;(iii) start in-licensing negotiations ...
Voir le projet